@misstealjedi1's Zepbound progress claim, fact-checked
Quick answer
The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript. The content is consistent with patient-reported outcomes on dual GIP/GLP-1 agonist therapy, where gradual body weight reduction over months is clinically expected based on SURMOUNT-1 trial data. No specific dosing, treatment protocols, or disease cure claims were identified in the available transcript.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @misstealjedi1 actually say?
Honestly? Not much that can be fact-checked. The transcript captured here is song lyrics, not health claims. The words "slits in the face, all I want for you" appear to be audio from a trending sound, not original spoken content about GLP-1 medications or weight loss.
What we do have is context: the caption reads "It's progress" with a heart emoji, paired with hashtags including #glp1, #zepboundcommunity, and #glp1forweightloss. The video likely shows a visual progress update, a before-and-after style clip, or a body transformation moment set to music. That format is extremely common in the Zepbound community on TikTok, where users document their weight loss journeys without making explicit medical claims.
So there are no direct spoken health claims to fact-check here. What we can do is look at what this type of content implies and whether those implications hold up.
Does the science back this up?
If the implicit claim is that tirzepatide (Zepbound) produces meaningful, visible weight loss progress, yes, the evidence is strong. This is one of the better-supported outcomes in recent obesity medicine research.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) followed 2,539 adults with obesity over 72 weeks. Participants on the highest dose of tirzepatide (15 mg) lost an average of 20.9% of their body weight. That is not a rounding error. For context, earlier GLP-1 agents like liraglutide produced roughly 5-8% weight loss in comparable trials.
Progress posts like this one, showing incremental change over weeks or months, align with how tirzepatide actually works. It is not a fast drug. Most users see gradual loss over a year or more, with results varying significantly by dose, diet, and individual metabolism. The "progress" framing is clinically reasonable.
What did they get wrong (or right)?
There are no explicit claims to flag as wrong here, which is actually worth noting. A lot of GLP-1 content on TikTok overclaims: people say things like "this cured my food noise" or "I stopped taking insulin" without context. This post does not appear to do that.
What the content does right is keep it personal. "It's progress" is not a medical claim. It is a personal update. That kind of framing avoids the trap many creators fall into, positioning their individual experience as universal or prescriptive.
The one mild concern is the hashtag #glp1forweightloss, which lumps multiple drugs together. GLP-1 receptor agonists vary significantly in their mechanisms and outcomes. Tirzepatide is a dual GIP/GLP-1 agonist, not a pure GLP-1 drug. Semaglutide, liraglutide, and tirzepatide are not interchangeable, and content that implies they are does a disservice to people trying to understand their options.
What should you actually know?
Progress on GLP-1 or dual-agonist medications is real, documented, and for many people, significant. But a few things often get lost in the scroll.
- Weight loss results vary widely. SURMOUNT-1 showed a range from minimal loss to over 25% body weight reduction. The average is not everyone's experience.
- These medications require ongoing use. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed that stopping semaglutide led to regain of roughly two-thirds of lost weight within a year.
- Side effects are common, especially early on. Nausea, vomiting, and GI discomfort affect a significant portion of users, particularly during dose escalation.
- Compounded versions of these drugs are not equivalent to brand-name Zepbound or Wegovy. Formulation, inactive ingredients, and quality controls differ. Do not assume a compounded tirzepatide produces the same result as the FDA-approved product.
- Progress posts are motivating but not medical advice. What worked for one person on one dose at one point in their journey is not a template.
If you are considering a GLP-1 or dual-agonist medication, talk to a licensed provider who can review your full health history, not just your TikTok feed.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @misstealjedi1's Zepbound progress claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript.
FormBlends verdict
The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript. The content is consistent with patient-reported outcomes on dual GIP/GLP-1 agonist therapy, where gradual body weight reduction over months is clinically expected based on SURMOUNT-1 trial data. No specific dosing, treatment protocols, or disease cure claims were identified in the available transcript.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video appears to be a personal weight loss progress post from a Zepbound (tirzepatide) user, with no explicit medical claims made in the transcript. The content is consistent with patient-reported outcomes on dual GIP/GLP-1 agonist therapy, where gradual body weight reduction over months is clinically expected based on SURMOUNT-1 trial data. No specific dosing, treatment protocols, or disease cure claims were identified in the available transcript.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15mg produced an average 20.9% body weight reduction over 72 weeks in adults with obesity.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It is not clinically equivalent to semaglutide or liraglutide despite shared hashtags.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15mg produced an average 20.9% body weight reduction over 72 weeks in adults with obesity.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug. It is not clinically equivalent to semaglutide or liraglutide despite shared hashtags.
- Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed roughly two-thirds of weight lost on semaglutide was regained within a year of stopping, suggesting these are long-term medications for most users.
- Compounded tirzepatide is not the same as FDA-approved Zepbound. Formulation, quality control, and inactive ingredients differ and are not regulated equivalently.
- Individual results vary significantly. SURMOUNT-1 participants ranged from minimal responders to those losing over 25% of body weight, so one person's progress post is not a benchmark.
- GI side effects including nausea and vomiting are common during dose escalation and affect a substantial portion of users in clinical trials.
- This specific video contains no spoken health claims and no prescriptive medical advice, which puts it in a lower-risk category compared to much GLP-1 content circulating on TikTok.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Miss Teal Jedi · TikTok creator
151.1K views on this video
It’s progress ❤️ #glp1 #zepboundcommunity #glp1forweightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Miss Teal Jedi, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.